Breast cancer

Cancer cells
#American Society of Clinical Oncology #Breast cancer #Cancer research #HER2 #Oncology #The College of American Pathologists

Updates to HER2 testing guidelines reduces confusion 

The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) have reaffirmed the Human Epidermal Growth Factor Receptor 2 (HER2) Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results.  The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that a treatment traditionally… Read More

#Cancer Research #News #Regulatory #Trending News

Breast cancer
#ASCO #Breast cancer #Cancer research #Novartis #Oncology #Phase III trial

Drug reduced the risk of breast cancer recurrence by 25%

Positive primary endpoint data from Novartis’ pivotal Phase III NATALEE trial has been presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2%… Read More

#Cancer Research #News #Trending News

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More

#News #Regulatory #Trending News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen a number of developments in the treatment of solid tumours… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

This week in drug discovery (20-24 March)

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in… Read More

#News

#Autoimmune disease #Breast cancer #Cancer immunotherapy #Clinical trials #Immunotherapy #LAG-3

Phase II/III trial to assess LAG-3 immunotherapy in breast cancer 

Immutep, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, has initiated AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and Paclitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (efti) in combination with paclitaxel for the treatment of metastatic HER2-neg/low breast cancer (MBC).  … Read More

#News

Cancer cell
#Breast cancer #Cancer research #Cancer treatment #Drug development #Drug discovery #Oncology

New global cancer research DDW eBook

This latest ebook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research.  Download this exclusive eBook to learn more about:  The global developments tackling the burden of cancer  … Read More

#News

Global cancer research eBook
#Breast cancer #Cancer research #Cancer treatment #Drug development #Drug discovery #Oncology

Global cancer research: Where are the breakthroughs?

This latest eBook sponsored by Sino Biological features insight on how the global drug discovery and development sector is making breakthroughs in cancer research.  Download this exclusive eBook to learn more about:  The global developments tackling the burden of cancer   Advances and challenges… Read More

#DDW eBooks #Intelligence

Cancer cell
#Breast cancer #Breast Cancer Now #Cancer research #Institute of Cancer Research #Oncology

New discovery could help prevent secondary breast cancer

Scientists have discovered why breast cancer cells that have spread to the lungs may ‘wake up’ following years of sleep – forming incurable secondary tumours. Patients with oestrogen receptor positive (ER+) breast cancer – the most common type – have a continued risk of their cancer… Read More

#Cancer Research #News #Trending News

Breast cancer treatment
#Antibody drug conjugate (ADC) #Breast cancer #Cancer research #FDA #Gilead Sciences #GlobalData #Oncology

ADC potential “standard of care” for some breast cancer patients

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting.  The drug is expected to become a standard of care for these patients,… Read More

#News #Trending News

Clinical trials
#Breast cancer #Cancer research #Clinical research #Clinical trials #Covid-19 #Oncology

What are the top disease areas for clinical drug trials?

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. Here, we take a look at the top four disease areas and some of the key developments in 2022.  1. Breast cancer In April, Biotech ISA… Read More

#Exclusive Content

#Breast cancer #Cancer research #Clinical trial design #Clinical trials #Drug development #Drug discovery #Oncology #Phase III trial

This week in drug discovery (6-10 February)

News round-up for 6-10 February by DDW Digital Content Editor Diana Spencer.  Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient… Read More

#News

Patient having a mammogram
#Breast cancer #Cancer research #Clinical research #Clinical trials #Oncology #Phase II trial

Breast cancer still top disease area for clinical studies

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi.  The company’s global analysis of all clinical trials conducted in 2022 showed that Covid-19 came second.   Three of… Read More

#Cancer Research #News

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

The DDW Highlights Podcast: World Cancer Day 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As 4 February was World Cancer Day, this week’s update focused on… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

This week in drug discovery (30 January – 3 February)

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer.  As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will … Read More

#News

Cancer cells
#Breast cancer #Cancer research #FDA #Gene mutation #Genetics / genomics #Menarini #Oncology #Stemline Therapeutics

FDA-approved therapy targets ESR1 mutations in breast cancer

The first and only treatment specifically indicated for patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer has been approved in the US.  The Food and Drug Administration (FDA) has approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced… Read More

#News #Regulatory